ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Saturday, 21 November 2026 Every NSE & BSE earnings call, live and summarised
ALFA Concalls Every earnings call, live and summarised

Q2 FY27 Earnings Call

Jubilant Pharmova Q2 FY27 Earnings Call

The call ran from 8:29 AM to 9:17 AM IST (48 min).

Key takeaways

Revenue rose 21% YoY to ₹2,370 Cr, but PAT was only ₹31 Cr as margins fell on Montreal losses (>₹80 Cr in Q2). Management guides H2 mid-teen margins and deferred FY28 guidance.

Highlights
Revenue growthQ2 revenue +21% YoY to ₹2,370 Cr; H1 +19% to ₹4,599 Cr.
MarginsEBITDA margins fell YoY; H2 guided mid-teens, improving QoQ.
Order bookLine 4 book strongest ever; 23 active proposals; no order book figure disclosed.
Demand visibilityUS isolator demand strong; Line 4 RFPs at record; 23 active proposals.
Management confidenceBalanced; confident H2 recovery, but FY28 guidance deferred.

Growth

Q2 revenue +21% YoY, H1 +19%; broad-based, but EBITDA margins fell YoY on Montreal and SPECT shortfall.

Outlook

H2 average EBITDA margin mid-teens; FY27 capex ₹1,800–1,900 Cr, FY28 ~₹1,000 Cr; net debt ~₹4,000 Cr end-FY27.

Risks

Montreal losses (₹157 Cr H1 plus ~₹200 Cr earlier) and SPECT supply gaps; FY28 guidance deferred; API pricing pressure.

Last quarter's promises, checked

Delivered

  • Guided FY27 growth 'low double digits' → H1 +19% (= BEAT)

Partly delivered

  • Guided Line 3 FY27 revenue $60–80M → ~$20M in Q2 (= PARTIAL)
  • Guided Ruby-Fill '30%+' growth → ~30% annualised Q2 (= PARTIAL)

Missed

  • Guided H2 EBITDA margin 17–18% → now 'mid-teens' (= MISS)
  • Guided Montreal FY27 loss ~FY26's ~₹200 Cr → H1 alone ₹157 Cr (= MISS)
  • Guided capex ~₹1,668 Cr and net debt falling from FY28 → capex ₹1,800–1,900 Cr, net debt ~₹4,000 Cr end-FY27 (= MISS)

Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published . Open it on ALFA Filings ›

The results behind this call

What management said last time

Full summary →

From the call summary published .

Outlook they gave

Guided H2FY27 EBITDA margins of 17-18%. Committed to net debt zero by 2030. Commencing commercial production on Line 3 late FY2027.

Growth they described

FY26 Revenue up 14% to ₹8,280 Cr; EBITDA up 8% to ₹1,326 Cr; Normalized PAT up 7% to ₹4,422 Cr.

Call details

CompanyJubilant Pharmova Ltd
NSE symbolJUBLPHARMA
ISININE700A01033
CallQ2 FY27 earnings call
DateMonday, 16 November 2026
Time8:30 AM IST
Length48 min

Jubilant Pharmova Ltd: key numbers

Share price
₹935.05
Market cap
₹14,894 Cr
Revenue (annual)
₹8,280 Cr
Net profit (annual)
₹398.5 Cr
P/E (TTM)
56.6×Sector 49.0×
Promoter holding
47.68%+0.00% QoQ
FII holding
15.37%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Other calls on Mon, 16 Nov

Today's concalls →

SS Retail

SSRETAILQ2 FY27 earnings call

Ended

ABB India

ABBQ2 FY27 earnings call

Ended